# Riposte Capital

Riposte Capital is an Asset Manager based in New York, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2010
- **Assets under management:** Undisclosed
- **Website:** riposecap.com
- **LinkedIn:** https://www.linkedin.com/company/riposte-capital

## Regulatory record

- **CRD number:** 322217
- **SEC file number:** 801-126026
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/322217

## About

RIPOSTE CAPITAL LLC is an SEC-registered investment adviser in NEW YORK, NY, registered since 2022. The firm manages approximately $497 million in regulatory assets. It has 9 employees and 5 investment advisers.

## Sectors

- Healthcare Services
- Digital Health
- Enterprise Software

## People

- Khomeiny M. Farhad — Founder and Chief Investment Officer

## Questions

### Who runs investment decisions at Riposte Capital?

Khomeiny Farhad is the founder and chief investment officer. He makes all portfolio decisions directly, having previously traded healthcare equities at PointState Capital and Citadel. The firm operates with a lean team that supports Farhad's research and execution.

### What is Riposte Capital's investment strategy?

The firm runs a concentrated long/short equity strategy focused on healthcare and technology. The long book targets undervalued or misunderstood companies, while the short book often involves activist campaigns where Riposte publishes research alleging fraud or mismanagement. Public campaigns have targeted companies including MiMedx and Novocure.

### How does Riposte Capital source its short ideas?

Riposte relies on primary, forensic research conducted internally. Farhad and his team analyze financial statements, clinical trial data, and sales practices to identify discrepancies that suggest overvaluation or fraud. The firm then builds positions before publishing detailed reports to influence market perception, a model documented in coverage of its MiMedx short (per WSJ, 2019).

### What is Riposte Capital's track record with activist short campaigns?

Riposte's most prominent campaign involved MiMedx, a wound-care company that ultimately restated several years of financial results following a series of short-seller reports including Riposte's. The firm has also publicly challenged Novocure's business practices. More recently, in early 2023, Riposte took an activist stake in ViewRay to push for operational changes.

## Related profiles

- [Ripgale](https://altss.com/profile/ripgale)
- [Ripple Care](https://altss.com/profile/ripple-care)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/riposte-capital-llc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology